On 14 October 2011, Teva Pharmaceutical Industries Ltd. (Teva) obtained conditional antitrust clearance from the European Commission and completed its US$6.8 billion acquisition of Cephalon. The deal closed one week after the US Federal Trade Commission (FTC) announced that Teva had agreed to divest a generic cancer pain drug and muscle relaxant. Additionally, the FTC is requiring Teva to enter into a supply agreement for a generic version of its narcolepsy drug Provigil in the US.